Market Share of Cystic Fibrosis (CF) Therapeutics Industry
The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.
The players operating in the market focus on introducing new products to address the changing needs of the patients. For instance, in April 2019, the US Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Incorporated's KALYDECO (ivacaftor) with an aim of expanding the range of treatment options for the millions of children living with cystic fibrosis (CF). This allows physicians to begin treating the underlying cause of CF in eligible infants as young as six months of age for the first time, with the potential to modify the course of the disease.
Cystic Fibrosis Therapeutics Market Leaders
-
AbbVie Inc
-
Gilead Sciences, Inc
-
Mylan N.V
-
Alaxia
-
Vertex Pharmaceuticals Incorporated
*Disclaimer: Major Players sorted in no particular order
_Therapeutics_Market_CL.webp)
